Amgen Cuts Repatha's Price 60% as Scrutiny of Drug Costs Heats Up Print
Written by FHI's Week in Review   
Monday, 29 October 2018 11:03
Patrice Wendling reports for Medscape on October 24, 2018:
Amgen announced today it is lowering the cost of its cholesterol-lowering drug, evolocumab ( Repatha), by roughly 60%. The move was designed to increase demand by lowering out-of-pocket costs, especially for Medicare patients, who currently pay between $280 and $370 a month in out-of-pocket costs, but will now pay $25 to $150 a month, Amgen officials said in a telephone press briefing.
Read more in the current issue of Week in Review>>
Last Updated on Monday, 29 October 2018 11:11